Publicaciones en las que colabora con Ana Fortuño Gil (43)

2017

  1. Increased phagocytic NADPH oxidase activity associates with coronary artery calcification in asymptomatic men

    Free Radical Research, Vol. 51, Núm. 4, pp. 389-396

  2. Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites

    Scientific Reports, Vol. 7

2014

  1. A role for cardiotrophin-1?

    Hypertension, Vol. 63, Núm. 3, pp. 468-474

2013

  1. A synthetic peptide from transforming growth factor-β1 Type III receptor inhibits NADPH oxidase and prevents oxidative stress in the kidney of spontaneously hypertensive rats

    Antioxidants and Redox Signaling, Vol. 19, Núm. 14, pp. 1607-1618

  2. Decreased Nox4 levels in the myocardium of patients with aortic valve stenosis

    Clinical Science, Vol. 125, Núm. 6, pp. 291-300

2012

  1. Blockade of TGF-β 1 signalling inhibits cardiac NADPH oxidase overactivity in hypertensive rats

    Oxidative Medicine and Cellular Longevity

2011

  1. Relación entre las fases precoces de la enfermedad renal y el síndrome metabólico

    Revista Espanola de Cardiologia, Vol. 64, Núm. 5, pp. 373-378

  2. The A640G CYBA polymorphism associates with subclinical atherosclerosis in diabetes

    Frontiers in Bioscience - Elite, Vol. 3 E, Núm. 4, pp. 1467-1474

  3. ¿el síndrome metabólico en España necesita más estudios descriptivos o más evidencia de su implicación en prevención secundaria? Respuesta

    Revista Espanola de Cardiologia

2010

  1. Is leptin involved in phagocytic NADPH oxidase overactivity in obesity? Potential clinical implications

    Journal of Hypertension, Vol. 28, Núm. 9, pp. 1944-1950

  2. Protective effect of the 1742(C/G) polymorphism of human cardiotrophin-1 against left ventricular hypertrophy in essential hypertension

    Journal of Hypertension, Vol. 28, Núm. 11, pp. 2219-2226

  3. The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: Potential implication in hypertension (Clinical Science (2009) 116, (233-240))

    Clinical Science

2009

  1. Insulin resistance determines phagocytic nicotinamide adenine dinucleotide phosphate oxidase overactivation in metabolic syndrome patients

    Journal of Hypertension, Vol. 27, Núm. 7, pp. 1420-1430

  2. Insulin-induced NADPH oxidase activation promotes proliferation and matrix metalloproteinase activation in monocytes/macrophages

    Free Radical Biology and Medicine, Vol. 46, Núm. 8, pp. 1058-1067

  3. The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: Potential implication in hypertension

    Clinical Science, Vol. 116, Núm. 3, pp. 233-240

2008

  1. NADPH oxidase CYBA polymorphisms, oxidative stress and cardiovascular diseases

    Clinical Science, Vol. 114, Núm. 3-4, pp. 173-182

2007

  1. A novel CYBA variant, the -675A/T polymorphism, is associated with essential hypertension

    Journal of Hypertension, Vol. 25, Núm. 8, pp. 1620-1626

  2. Oxidative stress, endothelial dysfunction and cerebrovascular disease

    Cerebrovascular Diseases

  3. Phagocytic NADPH oxidase-dependent superoxide production stimulates matrix metalloproteinase-9: Implications for human atherosclerosis

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 27, Núm. 3, pp. 587-593

2006

  1. Phagocytic NADPH oxidase overactivity underlies oxidative stress in metabolic syndrome

    Diabetes, Vol. 55, Núm. 1, pp. 209-215